Form 4 for CGEM Cullinan Therapeutics, Inc.

Accepted 2022-01-13 00:00:00 ET · period of report 2022-01-11 · accession 0000899243-22-001926 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2022-01-13	2022-01-11	CGEM	Jovan-Embiricos Morana	10%	J - Other	—	-1.19M	1.72M	-41%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-01-11	J	D	1,187,734	—	1,724,611	D	—	—	(F1) On January 11, 2022, F2 Vision SCS ("F2 Vision") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the "Shares") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. (F2) These securities are owned directly by F2 Vision. F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.